Roivant Plots ‘Streamlined’ Phase III As Ulcerative Colitis Data Raise Blockbuster Potential

The company announced data from the Phase IIb TUSCANY-2 trial of RVT-3101, which is in a tight race with PRA023 from Prometheus, which Merck recently acquired for $10.8bn.

Ulcerative colitis endoscopic biopsy
Roivant announced Phase IIb results for RVT-3101 in ulcerative colitis • Source: Shutterstock

Data from Roivant Sciences Ltd.’s Phase IIb TUSCANY-2 trial of RVT-3101 set the anti-TL1A antibody up as a potential blockbuster treatment for ulcerative colitis amid what looks to become stiff competition with competitor PRA023 from Prometheus Biosciences, Inc, which Merck & Co., Inc. recently acquired.

Following previously disclosed induction phase data from TUSCANY-2, Roivant announced results on 22 June for all-comers as well as those...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D